CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
3.970
+0.170 (4.47%)
May 8, 2026, 12:33 PM EDT - Market open
CervoMed Revenue
In the year 2025, CervoMed had annual revenue of $4.01M, down -58.86%. CervoMed had revenue of $8.73K in the quarter ending December 31, 2025, a decrease of -99.60%.
Revenue (ttm)
$4.01M
Revenue Growth
-58.86%
P/S Ratio
8.78
Revenue / Employee
$267,101
Employees
15
Market Cap
36.76M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.01M | -5.73M | -58.86% |
| Dec 31, 2024 | 9.74M | 2.59M | 36.29% |
| Dec 31, 2023 | 7.14M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 71.67K | -302.88K | -80.87% |
| Dec 31, 2012 | 374.54K | -195.93K | -34.35% |
| Dec 31, 2011 | 570.48K | 530.29K | 1,319.48% |
| Dec 31, 2010 | 40.19K | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | 40.19K | -268.57K | -86.98% |
| Dec 31, 2007 | 308.76K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veru Inc. | 16.89M |
| Apollomics | 8.84M |
| Evaxion | 7.53M |
| Pluri | 1.34M |
| Werewolf Therapeutics | 1.14M |
CRVO News
- 16 days ago - CervoMed presents neflamapimod MRI data - TheFly
- 16 days ago - CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies - GlobeNewsWire
- 4 weeks ago - CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting - GlobeNewsWire
- 6 weeks ago - CervoMed Transcript: The 38th Annual Roth Conference - Transcripts
- 7 weeks ago - CervoMed’s neflamapimod shows efficacy in dementia with DLB - TheFly
- 7 weeks ago - CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod's Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer's Disease Co-Pathology - GlobeNewsWire
- 7 weeks ago - CervoMed price target lowered to $11 from $19 at Roth Capital - TheFly
- 7 weeks ago - CervoMed price target raised to $21 from $15 at Chardan - TheFly